PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress

This study reveals that PI3K-AKT pathway hyperactivation is a critical determinant of oncogenic RAS-induced hypertranscription and replication stress, explaining variability between RAS isoforms and highlighting PI3K inhibition as a potential therapeutic strategy to mitigate transcription-replication conflicts in cancer.

The Gist

Imagine your body is a bustling city, and your cells are the workers in the factories that keep it running. Normally, these workers follow strict schedules: they build things, take breaks, and stop when the boss says so.

But in cancer, a "boss" named RAS gets mutated. It's like a boss who has lost its mind and is screaming, "BUILD MORE! BUILD FASTER! NEVER STOP!" This causes the factory to go into overdrive, a state scientists call hypertranscription. The workers are frantically copying blueprints (making RNA) to build more products, but they are doing it so fast that they start tripping over each other.

This chaos leads to Replication Stress. Imagine the factory floor is a busy highway. The workers (transcription machinery) are running across the lanes, while the delivery trucks (replication machinery) are trying to drive through. When they crash into each other, it causes traffic jams and accidents. These "accidents" are breaks in the DNA, which can lead to cancer getting worse or becoming resistant to treatment.

The Big Discovery: It's Not Just One Boss

For a long time, scientists thought that if you had a crazy RAS boss, the problem was just that the MAPK pathway (the "Speed Line") was too loud. They thought if you just turned down the volume on the speed, the chaos would stop.

But this paper, by Kelly and colleagues, says: "Not so fast!"

They compared three different types of crazy RAS bosses: HRAS, KRAS, and BRAF.

• HRAS is the most destructive. It causes massive traffic jams and factory accidents.
• KRAS and BRAF are also crazy, but they cause much fewer accidents.

Why the difference? The researchers found that HRAS doesn't just scream "Go Faster!" (MAPK); it also turns on a second, hidden engine called the PI3K-AKT pathway.

The Analogy: The Gas Pedal and the Turbo

Think of the cell as a car:

1. MAPK is the gas pedal. It tells the car to go fast.
2. PI3K-AKT is the turbocharger. It forces the engine to work even harder and builds more fuel (ribosomes) to keep the speed up.

• KRAS and BRAF only press the gas pedal. The car goes fast, but it's manageable.
• HRAS presses the gas pedal and slams the turbocharger on. The car is now moving at a dangerous, uncontrollable speed, causing it to crash into everything (DNA damage).

The "Turbo" Effect: Building Too Much

The PI3K-AKT "turbo" does something specific: it tells the cell to build ribosomes (the machines that make proteins) and snoRNAs (tiny helpers for those machines).

It's like the factory manager suddenly ordering 1,000 new assembly lines to be built overnight. The workers are now so busy building these new machines that they are running everywhere, creating a massive mess. This "hyper-transcription" is what causes the traffic jams (Replication Stress).

The Solution: Turning Off the Turbo

The researchers tested a simple idea: What if we turn off the turbo (PI3K) while leaving the gas pedal (MAPK) alone?

• Result: When they blocked the PI3K pathway, the "HRAS" cells calmed down. The traffic jams disappeared, and the DNA stopped breaking.
• Conversely: When they artificially turned on the turbo in cells that only had the "KRAS" gas pedal, suddenly those cells started crashing too!

Why This Matters for Patients

This is a game-changer for understanding cancer.

1. Not all RAS cancers are the same: A patient with an HRAS mutation might have a much more aggressive cancer with more DNA damage than a patient with a KRAS mutation, simply because HRAS turns on the "turbo" harder.
2. New Treatment Targets: Many cancer drugs target the "gas pedal" (MAPK inhibitors). But this paper suggests that for some cancers, we also need to turn off the "turbo" (PI3K inhibitors).
3. The "Double Trouble" Warning: The study looked at real cancer data and found that patients who have both a RAS mutation AND a PI3K mutation have the most chaotic factories of all. They have the highest levels of DNA damage. These patients might need a combination therapy: hitting both the gas and the turbo.

The Bottom Line

Cancer isn't just about driving fast; it's about how the car is built. This paper reveals that the PI3K-AKT pathway is the secret ingredient that turns a fast car into a wrecking ball. By understanding this, doctors can better predict which cancers will be dangerous and choose the right combination of drugs to stop the crash before it happens.

Technical Summary

1. Problem Statement

Oncogenic RAS mutations are drivers in approximately 10–15% of human cancers. These mutations lead to constitutive activation of downstream signaling pathways, primarily the MAPK (RAF-MEK-ERK) and PI3K-AKT pathways. A known consequence of RAS activation is replication stress, often caused by transcription-replication conflicts (TRCs) resulting from "hypertranscription" (excessive RNA synthesis).

However, a significant gap in understanding exists:

• Different RAS isoforms (HRAS, KRAS, NRAS) and other oncogenes (like BRAF) induce varying degrees of replication stress and genomic instability, yet the molecular determinants of this variability are unclear.
• While the MAPK pathway is well-known to drive proliferation, its specific role in causing hypertranscription and replication stress compared to the PI3K-AKT pathway remains debated.
• It is unclear whether S-phase entry alone or specific transcriptional programs are the primary drivers of these conflicts.

2. Methodology

The authors employed a multi-faceted approach combining cell biology, molecular genetics, and bioinformatics:

• Cell Models:
  • Used immortalized human BJ-hTERT fibroblasts with tamoxifen-inducible HRAS^G12V and KRAS^G12V, and doxycycline-inducible BRAF^V600E.
  • Generated a CaCo2 colon cancer line with inducible KRAS^G12V.
  • Created cell lines for inducible co-expression of oncogenic PI3K^E545K with KRAS^G12V or BRAF^V600E.
• Pharmacological Modulation:
  • Used small molecule inhibitors: PD0325901 (MEK), GDC-0941 (PI3K), Palbociclib (CDK4/6), and Rapamycin (mTORC1).
  • Used a small molecule activator: UCL-TRO-1938 (PI3K activator).
  • Used DRB (transcription inhibitor) to test the contribution of transcription to fork slowing.
• Assays for Replication Stress & Transcription:
  • DNA Fiber Assays: To measure replication fork progression speeds.
  • EU Incorporation: To quantify nascent RNA synthesis (hypertranscription).
  • S9.6 Slot Blots: To measure global RNA:DNA hybrid (R-loop) levels.
  • Immunofluorescence/Flow Cytometry: To assess DNA damage (53BP1 foci), micronuclei, senescence, apoptosis, and cell cycle distribution (EdU).
  • ROS Assay: To rule out reactive oxygen species as a cause of stress.
• Transcriptomics:
  • Steady-state RNA-seq: To analyze total gene expression changes.
  • Chromatin-bound RNA-seq (ChrRNA-seq): To specifically quantify nascent transcripts and RNA Polymerase activity (Pol I, II, III) without the noise of steady-state mRNA stability.
• Bioinformatics:
  • Analyzed TCGA Pan-Cancer Atlas datasets (specifically Colorectal Adenocarcinoma - COAD) to correlate driver mutations (KRAS, BRAF, PIK3CA) with hypertranscription scores and replication stress signatures.

3. Key Contributions

• Identification of PI3K-AKT as the Critical Driver: The study establishes that MAPK signaling alone is insufficient to induce significant hypertranscription or replication stress. Instead, PI3K-AKT hyperactivation is the primary determinant.
• Isoform-Specific Mechanism: The authors explain why HRAS induces more severe replication stress than KRAS or BRAF: HRAS hyperactivates the PI3K-AKT pathway significantly more than KRAS or BRAF, even when protein expression levels are comparable.
• Decoupling S-Phase Entry from Hypertranscription: The study demonstrates that while S-phase entry correlates with stress, it is not the cause. Hypertranscription and replication stress can occur even when S-phase entry is blocked, provided PI3K signaling is active.
• Transcriptional Targets: The paper identifies specific transcriptional programs driven by PI3K-AKT (via GSK3β inhibition and MYC stabilization) that lead to conflicts: specifically, the upregulation of ribosome biogenesis genes, snoRNAs, and RNA Pol I/III activity.

4. Detailed Results

A. Differential Impact of Oncogenes

• HRAS^G12V induced a ~2-fold increase in nascent RNA synthesis, high levels of RNA:DNA hybrids, slowed replication forks, and significant DNA damage (53BP1 foci).
• KRAS^G12V induced only a modest (~1.2-fold) increase in RNA synthesis and mild fork slowing.
• BRAF^V600E induced no significant increase in RNA synthesis or replication stress.
• Conclusion: The severity of replication stress correlates with the degree of PI3K-AKT activation, not just MAPK activation.

B. The Role of PI3K-AKT Signaling

• Western Blots: HRAS^G12V caused strong phosphorylation of AKT (T308/S473) and subsequent inhibition of GSK3β (via phosphorylation). KRAS and BRAF showed much weaker PI3K-AKT activation.
• Inhibition Studies: Treating HRAS^G12V cells with a PI3K inhibitor (GDC-0941) or MEK inhibitor (PD0325901) rescued replication fork slowing and reduced nascent RNA synthesis.
• Activation Studies:
  • Treating cells with the PI3K activator UCL-TRO-1938 caused replication fork slowing.
  • Co-expression of PI3K^E545K with BRAF^V600E (which normally causes no stress) resulted in significant hypertranscription and replication stress.
  • Co-expression of PI3K^E545K with KRAS^G12V did not exacerbate stress beyond KRAS alone, suggesting a threshold effect or specific synergy with BRAF.

C. Transcriptional Mechanisms

• Chromatin RNA-seq: HRAS^G12V upregulated genes involved in ribosome biogenesis, translation, and cell cycle.
• RNA Polymerase Activity:
  • RNA Pol I: HRAS increased 45S pre-rRNA synthesis (driven by MYC/RRN3).
  • RNA Pol III: HRAS increased tRNA and 5S rRNA synthesis.
  • RNA Pol II: Upregulation of E2F and MYC target genes, including TBP (TATA-box binding protein), which drives global transcription.
• Mechanism: PI3K-AKT inhibits GSK3β, which stabilizes MYC and Cyclin D1. High MYC drives the "universal amplifier" effect on all three RNA polymerases, leading to massive transcriptional load and TRCs.

D. Clinical Relevance (TCGA Analysis)

• Analysis of Colorectal Adenocarcinoma (COAD) samples showed that tumors with co-mutations of KRAS/BRAF and PIK3CA displayed:
  • Higher hypertranscription scores.
  • Higher replication stress mRNA signatures.
  • Increased frequency of Copy Number Alterations (CNAs) in Common Fragile Sites (WWOX, FHIT, MACROD2) compared to tumors with KRAS/BRAF mutations alone.

5. Significance

• Mechanistic Insight: The paper resolves the discrepancy between different RAS isoforms in causing genomic instability, pinpointing PI3K-AKT hyperactivation as the key variable.
• Therapeutic Implications:
  • It suggests that PI3K inhibitors could be effective in reducing replication stress in RAS-mutant cancers, potentially sensitizing them to DNA damage response (DDR) inhibitors (e.g., PARP, ATR, WEE1 inhibitors).
  • It highlights that cancers with co-occurring PIK3CA and RAS/BRAF mutations may be particularly vulnerable to therapies targeting transcription-replication conflicts.
• Biomarker Potential: The study proposes that high levels of MYC activity, E2F targets, and ribosome biogenesis gene expression could serve as biomarkers for identifying tumors with high replication stress and potential sensitivity to TRC-targeting therapies.

In summary, Kelly et al. demonstrate that PI3K-AKT signaling is the critical switch that converts oncogenic RAS signaling into a state of hypertranscription and replication stress, primarily through the stabilization of MYC and the subsequent over-activation of RNA polymerases I, II, and III.